Literature DB >> 29899573

Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy.

M E Martínez-Muñoz1,2, R Forés1,2, A Lario1, G Bautista1,2, J L Bueno1,2, C de Miguel1,2, B Navarro1,2, A De Laiglesia1,2, A Sánchez-Guerrero2,3, J R Cabrera1,2, R F Duarte4,5.   

Abstract

Entities:  

Year:  2018        PMID： 29899573     DOI： 10.1038/s41409-018-0256-8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  4 in total

1.  Serious Hemorrhagic Complications After Successful Treatment of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy With Defibrotide in Pediatric Patient With Myelodysplastic Syndrome.

Authors:  Alexandra Laberko; Marina Aksenova; Irina Shipitsina; Igor Khamin; Anna Shcherbina; Dmitry Balashov; Alexei Maschan
Journal:  Front Pediatr       Date:  2020-05-05       Impact factor: 3.418

2.  [Chinese consensus on the diagnosis and management of transplant-associated thrombotic microangiopathy (2021)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-03-14

Review 3.  Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis.

Authors:  Joanna A Young; Christopher R Pallas; Mary Ann Knovich
Journal:  Bone Marrow Transplant       Date:  2021-04-19       Impact factor: 5.174

Review 4.  Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy.

Authors:  Eleni Gavriilaki; Vincent T Ho; Wilhelm Schwaeble; Thomas Dudler; Mohamed Daha; Teizo Fujita; Sonata Jodele
Journal:  Exp Hematol Oncol       Date:  2021-12-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.